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Summarn Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of munrne tumour
models. The recommended schedule, of intravenous (i-v.) bolus administration at a dose of 2 mg m every 3
weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the
drug was fairly well tolerated, but the response rate was disappointing: 0 18. colorectal cancer: 0 18. renal
cancer: I partial response (PR) 17. ovarian cancer.
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Rhizoxin is a tubulin-binding cytotoxic compound, isolated
from the fungus Rhizopus chinensis, with significant anti-
neoplastic activity in several munrne and human tumour
models (Tsuruo et al., 1986; Takahashi et al., 1987). In a
previous phase I study, the drug was administered by i.v.
bolus injection at 3 week intervals. Twenty-four patients with
refractory solid tumours were treated; 60 courses of rhizoxin
were given, at doses ranging from 0.8 to 2.6 mg m-2. Grade 3
mucositis, grade 4 leucopenia and grade 3 diarrhoea were
dose limiting but reversible at 2.6 mg m2, the maximum
tolerated dose for both previously untreated and heavily
pretreated patients. Alopecia and moderate discomfort at the
injection site occurred at all doses. Other side-effects, includ-
ing peripheral neuropathy, phlebitis and nausea and vomi-
ting, were sporadic and mild. Two heavily pretreated patients
with recurrent breast cancer had minor responses to rhizoxin,
one at 1.6 mg m-2 and the other at 2.6 mg m-2. Plasma
concentrations of rhizoxin were measured by high-per-
formance liquid chromatography and showed considerable
inter-subject variation in the plasma concentration-time
profiles; the area under the curve ranged from 0.29 to
0.96 ;tg ml-' min-'. Rhizoxin has shown some clinical act-
ivity in the phase I study and a dose of 2.0 mg m2
administered by i.v. bolus every 3 weeks was recommended
for phase II studies (Bissett et al., 1992). The Cancer
Research Campaign Phase II Trials Committee therefore
initiated three studies to assess the efficacy of rhizoxin in the
treatment of ovarian, renal and colorectal cancer, in coll-
aboration with the Early Clinical Trial Group of the EORTC
which performed phase II trials in breast, head and neck and
non-small-cell lung cancer using the same protocol.
Patnts and methods
Eligibility criteria common to the three studies were as fol-
lows: histological diagnosis of ovarian, colorectal and renal
cancer; performance status (WHO scale) 2; life expectancy
>3 months; white blood count (WBC) >4000 mm-3;
platelets >100000mm-3; creatinine 150 lmol 1-'; bili-
rubin <20ymol 1-1; uni- or bidimensionally measurable
lesions with documented progression within 2 months before
the study. Previous immunotherapy but not chemotherapy
was permissable in patients with renal cancer. In ovarian
cancer, patients should have received no more than one
previous chemotherapy regimen in the 12 months before
entry and no chemotherapy during the 4 months before
entry. Colorectal cancer patients may not have received more
than one chemotherapy regimen for advanced disease.
The drug was provided by Fujisawa Pharmaceutical
(Japan) and was provided as a vacuum dried powder (5 mg
of rhizoxin, 25 mg ofmannitol and 25 mg of ascorbic acid) in
a duopack which contains special diluent vials [2.5 ml of
diluent, 80% (v,v) propylene glycol and 20% (v v) ethanol].
The vial of rhizoxin was dissolved in 2.5 ml of special diluent
and then 2.5 ml of sterile water was added giving a stock
solution of 1 mgml', stable for 8 h at room temperature.
Rhizoxin was administered by i.v. bolus into a peripheral
vein at 2 mg m-' every 3 weeks. When treatment had to be
delayed for I week because of myelosuppression (WBC
<3.0, platelets <100), the next course was given at 75%
previous dose. Similarly, for patients who developed >
grade 3 toxicity other than haematological, the decision to
have therapy withheld or reduced to 75% was left to the
investigators' discretion. Patients were evaluable for response
after two courses of therapy; treatment was discontinued in
instances of progressive disease while its continuation was
left to the discretion of the investigator when there was no
significant change in tumour size. Objective UICC criteria
were used to assess response for measurable disease; non-
measurable disease was not used to assess response. CA125
was used as a subsidiary measure of response. Patients in
response remained on study until disease progression or
excessive toxicity. The CTC criteria for toxicity and UICC
criteria for response (in terms of target lesion size etc.) were
applied (Miller et al., 1981). All patients gave informed con-
sent in this multicentre study and the trial protocols received
local ethics committee support.
Results
Ovarian cancer
Twenty-two patients with progressive epithelial ovarian
cancer resistant to conventional chemotherapy were entered
in the study (Table I).
Five patients (two indications in one patient) were
regarded as ineligible for the following reasons: indicator
lesion previously irradiated (three patients), chemotherapy
within previous 4 weeks (one patient), endocrine therapy
within previous 4 weeks (one patient). previous malignancy
at another site (one patient). Of the 17 eligible women the
median age was 59 (range = 44-72 years). nine had a
performance status (PS) of 0. six a PS of 1 and two a PS of
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Table I Charateristics ofeligible patients
Ovarian cancer Colorectal cancer Renal cancer
(n= 17) (n= 18) (n = 18)
Characteristics
Median age (years) 59 63 55
Age range 44-72 36-70 35-70
Men/women 0/17 12/6 12/6
Performance statusa
0 9 6 4
1 6 8 10
2 2 3 4
Sites ofdisease
Primary tour 11 4 11
Local recurren 4 7 2
Metastatic nodes 6 3 6
Lung 2 4 13
Liver 7 12 2
Previous treatment
Surgery 16 18 12
Radiotherapy 1 2 4
Immunotherapy 1 3 3
Chemotherapy 17 13 0
None 0 0 4
'Performance status not known in one patient.
2. Twelve patients had had one prior platinum-based
chemotherapy regimen. Four had received two and one
patient three different regimens (one of which contained
taxol). In addition one patient had received interferon and
two, hormonal therapy. Fifty-six cycles of rhizoxin were
delivered to the 17 eligible patients (range= 1-7 cycles). The
dose was not modified for any of the courses and treatment
delays were minimal (four patients, 1-3 days) and not for
reasons of toxicity.
Rhizoxin was fairly weli tolerated and the most common
toxicities included alopecia in 96% of courses (grade 1 and
2); lymphocytopenia in 78% of courses (grade 3, 25%);
fatigue in 48% of courses (grade 3, 4%); stomatitis in 29%
of courses (grade 3, 0%).
One patient who had received platinum-based chemo-
therapy previously had a partal response in a pelvic mass
and para-aortic lymphadenopathy which was apparent after
two cycles ofchemotherapy with a duration of 3 months. No
patients had a separate response using the CA125 criteria of
the study.
Colorectal cancer
Twenty patients with advanced colorectal cancer were
entered in the study (Table I). Two patients were ineligible
because they did not fulfil the entry criteria and are not
included for analysis. Seventeen of the 18 eligible patients
received at least two courses of rhizoxin 2 mg m-2 at 3
weekly intervals. Fourteen of the 18 eligible patients were
WHO performance status 0 or l. Four patients had more
than three sites of disease. A total of 58 courses were given,
with the mean number being three.
The most common toxicities were alopecia in 91l% of
courses (gades 1 and 2); tiredness in 45% of courses (grade
3, 5%); lymphocytopenia in 38% of courses (grade 3, 9%)
and stomatitis in 21% of courses (grade 3, 3%). Pain in
tumour-associated sites after administration of rhizoxin was
noted in three patients. Complete response in two liver
ksions was reported in one patient but disease progression at
other sites. OveralL therefore, no responses were seen.
Renal cncer
Twenty patients with advanced renal cancer were entered in
the study (Table I). Two patients were ineligible because they
did not fulfil the entry criteria and are not included for
analysis. The 18 eligible patients all received at least two
courses of rhizoxin 2 mgm-2 at 3 weekly intervals. Fourteen
ofthe 18 eligible patients were WHO performance status 0 or
1. Eleven of the patients still had a primary renal carcinoma
in situ and six patients had more than three sites of disease.
A total of 56 courses were given with the mean number being
three. One patient was entered with a serum creatinine
>150pmol 1-' but an EDTA clarance was 55mlminur
and was therefore eligible. This patient was the only patient
who required dosage reductions because of toxicity. Interest-
ingly, the only other patient with a serum creatinine
>140) mol 1-' did not suffer any WBC toxicity. Only one
course of treatment was delayed for clinical reasons (chest
infection).
The most common side-effects were alopecia in 96% of
courses (grade 1 and 2); tiredness in 77% ofcourses (grade 3,
4%); diarrhoea in 41% ofcourses (grade 3, 4%); nausea and
vomiting in 30% ofcourses (grade 3, 4%); fall in lymphocyte
count in 80% of courses (grade 3 and 4, 27%); and
stomatitis in 30% of courses (grade 3, 0%). No tumour
responses were seen.
The results of these studies with only one partial response
documented in ovarian cancer, suggests that at the tested
schedule of 2mgm-2 administered by i.v. bolus every 3
weeks, rhizoxin has no clinically relevant anti-tumour activity
in ovarian, colorectal or renal cancer. Similar patterns of
toxicity were seen in each of the three groups ofpatients with
moderate alopecia, lymphocytopenia and gastrointestinal tox-
icity as previously described in the phase I study (Bissett et
al., 1992).
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